Academic Journal
Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre
| العنوان: | Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre |
|---|---|
| المؤلفون: | Bargagli E., Piccioli C., Rosi E., Torricelli E., Turi L., Piccioli E., Pistolesi M., Ferrari K., Voltolini L. |
| المساهمون: | Bargagli, E., Piccioli, C., Rosi, E., Torricelli, E., Turi, L., Piccioli, E., Pistolesi, M., Ferrari, K., Voltolini, L. |
| سنة النشر: | 2019 |
| المجموعة: | Università degli Studi di Siena: USiena air |
| مصطلحات موضوعية: | Idiopathic pulmonary fibrosi, Nintedanib, Pirfenidone |
| الوصف: | Background: Idiopathic pulmonary fibrosis has a median survival time after diagnosis of 2–5 years. The main goal of treating IPF is to stabilize or reduce the rate of disease progression. Nintedanib and Pirfenidone have been a breakthrough in the management of IPF. Here we evaluated the effectiveness of Pirfenidone and Nintedanib in a population of IPF patients diagnosed in the last 12 months at Florence ILD Referral Centre. Methods: In the last 12 months, 82 IPF patients (66 male, mean age 78.3 ± 23.8 years) were diagnosed and started antifibrotic therapy with Pirfenidone or Nintedanib. Their clinical and functional details were analyzed retrospectively at time 0 and after 6 and 12 months of therapy. Results: The median age of the patients treated with Nintedanib was higher than that of the Pirfenidone group (p < 0.0001). The most common symptoms at disease onset were exertional dyspnoea and dry cough with no differences between the two groups (p < 0.05). All IPF patients manifested bibasal crackles at the time of diagnosis. No significant differences in FVC, FEV1, TLC and DLCO were found at time 0 or after 6 months between patients treated with Pirfenidone and Nintedanib (p > 0.05). After 1 year, lung function test parameters of patients treated with Pirfenidone had remained stable from baseline. Discussion: This study emphasizes that both antifibrotic drugs appeared to be a good therapeutic choice in terms of functional stabilization, also in older patients. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | ELETTRONICO |
| اللغة: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/30236523; info:eu-repo/semantics/altIdentifier/wos/WOS:000470130400005; volume:25; issue:3; firstpage:149; lastpage:153; numberofpages:5; journal:PULMONOLOGY; http://hdl.handle.net/11365/1062454; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85053290319; https://www.sciencedirect.com/science/article/pii/S2531043718300990?via=ihub |
| DOI: | 10.1016/j.pulmoe.2018.06.003 |
| الاتاحة: | http://hdl.handle.net/11365/1062454 https://doi.org/10.1016/j.pulmoe.2018.06.003 https://www.sciencedirect.com/science/article/pii/S2531043718300990?via=ihub |
| Rights: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.CE4254B2 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.pulmoe.2018.06.003 |
|---|